BCMA

Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA 1:05
Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA
Hermann Einsele • 10 Feb 2023
Direct detection and isolation of CAR cells from patient samples 1:27
Direct detection and isolation of CAR cells from patient samples
Saskia Rösch • 6 Apr 2022
Targeting neoantigens in multiple myeloma with CAR T-cell 5:56
Targeting neoantigens in multiple myeloma with CAR T-cell
Angela Krackhard • 6 Apr 2022
Adoptive T cell therapies for solid tumors: what are the key challenges? 1:38
Adoptive T cell therapies for solid tumors: what are the key challenges?
Chris Klebanoff • 1 Apr 2022
Exciting advances in CAR-T and TCR research 2:49
Exciting advances in CAR-T and TCR research
David Gilham • 22 Feb 2021
Challenges of CAR T-cell therapy for AML: is CD38 the answer? 6:10
Challenges of CAR T-cell therapy for AML: is CD38 the answer?
Lei Yu • 3 Jun 2021
Innovations within the CAR T-cell field 1:40
Innovations within the CAR T-cell field
Hong Ma • 19 Feb 2021
CT053, anti-GPC3 CAR-T and targeting solid tumors 4:15
CT053, anti-GPC3 CAR-T and targeting solid tumors
Hong Ma • 19 Feb 2021
Progression of CAR-T trials in China 2:19
Progression of CAR-T trials in China
Jianxiang Wang • 2 Feb 2021
CAR-T trials to watch in China 3:21
CAR-T trials to watch in China
Jianxiang Wang • 2 Feb 2021
Implementation of CAR T-cell therapy in myeloma: practical and patient-related aspects 4:14
Implementation of CAR T-cell therapy in myeloma: practical and patient-related aspects
Maria-Victoria Mateos • 3 Feb 2021
Meta-analysis: anti-BCMA CAR-T in R/R myeloma 5:03
Meta-analysis: anti-BCMA CAR-T in R/R myeloma
Nico Gagelmann • 1 Sep 2020
CAR T-cells: current climate & future perspectives in myeloma 4:18
CAR T-cells: current climate & future perspectives in myeloma
Nico Gagelmann • 1 Sep 2020
The content of VJRegenMed is intended for healthcare professionals